According to a recent LinkedIn post from HistoSonics, the company is promoting two Device Tech Talk sessions at the American Urological Association Annual Meeting in Washington, D.C., focused on histotripsy for non-invasive tumor destruction and potential urologic applications. The talks feature clinicians Arun Rai, M.D., and Brian Shuch, M.D., and are scheduled for May 15 and 16 in the exhibit hall.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that HistoSonics staff will be available to discuss the Edison Histotripsy System at a separate booth on the exhibition floor, with a disclaimer that use outside liver applications is limited to clinical investigations. For investors, the emphasis on urologic applications and scientific engagement at AUA suggests the company is exploring broader clinical and commercial pathways for its platform, while the regulatory caveat underscores that expansion beyond liver indications remains at an investigational stage.